BRCA1 and Lynch syndrome: No surveillance strategies were cost-effective for moderate risk and low risk individuals (PALB2, BRCA1, BRCA2, Lynch syndrome, and TP53) and ICERs ranged from $330,000 – $48.5 million/QALY.